查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
人乳头瘤病毒疫苗市场 - 2018-2028 年全球行业规模、份额、趋势、机会和预测，按效价、疾病适应症、分销渠道、地区和竞争细分
市场调查报告书
商品编码
1321043

人乳头瘤病毒疫苗市场 - 2018-2028 年全球行业规模、份额、趋势、机会和预测，按效价、疾病适应症、分销渠道、地区和竞争细分

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Valence, By Disease Indication, By Distribution Channel, By Region, and By Competition
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

预计全球人乳头瘤病毒疫苗市场在 2024-2028 年预测期内将出现令人印象深刻的增长。人乳头瘤病毒相关疾病的发病率不断上升，以及政府和私营组织在全球范围内传播人乳头瘤病毒相关意识的倡议的增加，正在促进市场的增长。人乳头瘤病毒感染是由人乳头瘤病毒相关癌症（例如宫颈癌、阴茎癌和生殖器癌）引起的最常见的性传播污染。人乳头瘤病毒疫苗是针对某些类型的人乳头瘤病毒的免疫接种。它可以预防两种、四种或九种人类乳头瘤病毒。支持市场增长的因素包括治疗性疫苗开发研究的不断增加、大量临床试验、意识的提高和政府投资的增加、减少人乳头瘤病毒感染的需求不断增长等。根据 Clinical Trials.gov 的数据，截至 2022 年 11 月，全球约有 394 项与人乳头瘤病毒疫苗相关的临床研究处于不同的开发阶段。

人类乳头瘤病毒疾病病例不断增加

肛门、口咽和生殖器等不同器官的人乳头瘤病毒相关疾病病例激增，显着增加了对人乳头瘤病毒疫苗的需求，从而创造了利润丰厚的市场增长机会。市场上只有三种类型的疫苗：二价、四价和非价。这三种疫苗都能非常有效地避免 16 型和 18 型病毒的感染，这两种病毒可以治愈 70% 的宫颈癌病例。据美国疾病控制与预防中心 (CDC) 称，在美国，人乳头瘤病毒是最常见的性传播感染。 70%以上的外阴和阴道疾病、60%的阴茎恶性肿瘤、90%的肛门癌和宫颈肿瘤都是由人乳头瘤病毒引起的。此外，在女性中，宫颈癌在 9 岁至 30 岁之间非常常见，这刺激了对 HPV 疫苗的需求。例如，根据世界卫生组织的数据，2017年，宫颈癌导致全球超过25万女性死亡，其中85%发生在发展中国家。

政府和私人组织越来越多的倡议

在过去的几年中，各国政府和私人组织已采取多项措施来提高民众对乳头瘤病毒的认识，从而推动人乳头瘤病毒疫苗市场的增长。这反过来又增加了与人乳头瘤病毒疫苗相关的研发活动和产品的推出。例如，最近，印度推出了首款针对宫颈癌的四价人乳头瘤病毒疫苗（qHPV）。此外，Profectus Biosciences, Inc. 正在开发 GeneVax prime/VesiculoVax，一种 HPV 治疗疫苗。该疫苗被认为对七种人类乳头瘤病毒有效。此外，各组织，特别是联合国儿童基金会，多年来一直在努力提高疫苗的接受度。泛美卫生组织 (PAHO) 循环基金和联合国儿童基金会供应部门的影响使得不同国家能够以较低的价格获得疫苗。

市场细分

全球人乳头瘤病毒疫苗市场按效价、疾病适应症、分销渠道和公司细分。根据化合价，市场分为二价、四价、非价等。根据疾病适应症，市场分为宫颈癌、肛门癌、阴道癌、阴茎癌、外阴癌等。根据分销渠道，市场分为医院和诊所、政府和非政府组织、公共和私人联盟等。就国家而言，由于人类乳头瘤病毒相关疾病的患病率上升以及该国医疗基础设施的改善，预计美国在预测期内将成为一个利润丰厚的市场。

市场参与者

印度血清研究所列兵。 Ltd.、葛兰素史克公司、强生公司、默克公司、阿斯利康公司、诺华公司、Inovio Pharmaceuticals, Inc.、Xenetic Biosciences, Inc.、赛诺菲 SA 和 Bharat Biotech International Limited 是一些领先的公司在市场上经营的公司。

可用的定制

根据给定的市场数据，TechSci Research 可根据公司的具体需求提供定制服务。该报告可以使用以下自定义选项：

公司信息

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场细分

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要行业合作伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：临床试验分析

  • 正在进行的临床试验
  • 已完成的临床试验
  • 终止的临床试验
  • 按开发阶段分類的管道细目
  • 管道细分（按状态）
  • 按研究应用分類的管道细分
  • 按地区分類的管道明细
  • 临床试验热图

第 6 章：专利分析

第 7 章：全球人乳头瘤病毒疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按化合价（二价、四价、非价、其他）
    • 按疾病适应症（宫颈癌、肛门癌、阴道癌、阴茎癌、外阴癌、其他）
    • 按分销渠道（医院和诊所、政府和非政府组织、公共和私人联盟、其他）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图
    • 通过价
    • 按疾病适应症
    • 按分销渠道
    • 按地区

第 8 章：北美人乳头瘤病毒疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 通过价
    • 按疾病适应症
    • 按分销渠道
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 9 章：欧洲人乳头瘤病毒疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 通过价
    • 按疾病适应症
    • 按分销渠道
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第10章：亚太地区人乳头瘤病毒疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 通过价
    • 按疾病适应症
    • 按分销渠道
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第 11 章：南美洲人乳头瘤病毒疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 通过价
    • 按疾病适应症
    • 按分销渠道
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十二章：中东和非洲人乳头瘤病毒疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 通过价
    • 按疾病适应症
    • 按分销渠道
    • 按国家/地区
  • MEA：国家分析
    • 南非人乳头瘤病毒疫苗
    • 沙特阿拉伯人乳头瘤病毒疫苗
    • 阿联酋人乳头瘤病毒疫苗

第 13 章：市场动态

  • 司机
  • 挑战

第 14 章：市场趋势与发展

  • 最近的发展
  • 併购
  • 产品发布

第15章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（据报导）
  • 最近的发展
  • SWOT分析
    • Serum Institute of India Pvt. Ltd.
    • GlaxoSmithKline Plc.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • AstraZeneca Plc
    • Novartis AG
    • Inovio Pharmaceuticals, Inc.
    • Xenetic Biosciences, Inc.
    • Sanofi SA
    • Bharat Biotech International Limited

第 16 章：战略建议

简介目录
Product Code: 13006

Global human papillomavirus vaccine market is anticipated to observe impressive growth during the forecast period 2024-2028. Growing incidences of Human Papillomavirus Virus-related diseases, along with the rise in initiatives by government and private organizations to spread awareness related to human papillomavirus worldwide, are augmenting the growth of the market. Human papillomavirus infection is the most common sexually transmitted contamination caused by Human Papillomavirus Virus-related cancers such as cervical, penile, and genital cancer. Human papillomavirus vaccines are immunizations that protect from certain types of human papillomavirus. It protects against either two, four, or nine kinds of Human Papillomavirus Virus. The factors supporting the market's growth are the increasing research for the development of therapeutic vaccines, the large number of clinical trials, increasing awareness and government investments, growing need to reduce Human Papillomavirus Virus infections, among others. According to clinical trials.gov, as of November 2022, around 394 clinical studies are in different phases of development related to human papillomavirus vaccines across the globe.

Increasing Cases of Human Papillomavirus Diseases

Upsurge in the cases of Human Papillomavirus related diseases in different organs such as the anal, oropharynx, and genital parts has significantly raised the demand for Human Papillomavirus vaccines, thereby creating lucrative opportunities for market growth. There are just three types of vaccines in the market: bivalent, tetravalent, and nonvalent. All three vaccines are highly effective in avoiding infection with both virus types 16 and 18, which are liable for curing 70% of cervical cancer cases. According to the Centers for Disease Control and Prevention (CDC), in the United States, human papillomavirus is the most common sexually transmitted infection. Over 70% of vulvar and vaginal diseases, 60% of penile malignant growths, and 90% of anal cancer and cervical tumors are caused because of Human Papillomavirus. Moreover, in women, cervical cancer is very common among those age between 9 to 30, which spurs the need for the HPV vaccine. For instance, according to the WHO, in 2017, cervical cancer was liable for over 2,50,000 deaths of women globally, and 85% of these deaths occurred in developing countries.

Increasing Initiatives by Government & Private Organizations

Over the past few years, governments of different nations and private organizations have been taking several steps to create awareness among the population with regard to papillomavirus among the population, thereby driving the growth of the human papillomavirus vaccine market. This has, in turn, increased the research and development activities and products launched related to human papillomavirus vaccine. For instance, recently, India launched the first quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer. Also, Profectus Biosciences, Inc., is in the process of developing GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV. The vaccine is believed to be effective against seven Human Papillomavirus kinds. Furthermore, organizations, especially UNICEF, have made efforts to improve vaccine acceptance over the years. The impact of the Pan American Health Organization (PAHO) revolving fund and UNICEF supply division permits vaccinations to be acquired at lower prices for diverse nations.

Market Segmentation

Global human papillomavirus vaccine market is segmented into valence, disease indication, distribution channel, and company. Based on valence, the market is divided into bivalent, quadrivalent, nonvalent, and others. Based on disease indication, the market is categorized into cervical cancer, anal cancer, vaginal cancer, penile cancer, vulvar cancer, and others. Based on distribution channel, the market is segmented into hospitals & clinics, governmental & non-governmental organizations, public & private alliances, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising prevalence of human papillomavirus-related diseases and better healthcare infrastructure in the country.

Market Players

Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Novartis AG, Inovio Pharmaceuticals, Inc., Xenetic Biosciences, Inc., Sanofi SA, and Bharat Biotech International Limited are some of the leading companies operating in the market.

Report Scope

In this report, global human papillomavirus vaccine market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Human Papillomavirus Vaccine Market, By Valence:

  • Bivalent
  • Quadrivalent
  • Nonvalent
  • Others

Human Papillomavirus Vaccine Market, By Disease Indication:

  • Cervical Cancer
  • Anal Cancer
  • Vaginal Cancer
  • Penile Cancer
  • Vulvar Cancer
  • Others

Human Papillomavirus Vaccine Market, By Distribution Channel:

  • Hospitals & Clinics
  • Governmental & Non-Governmental Organizations
  • Public & Private Alliances
  • Others

Human Papillomavirus Vaccine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Human Papillomavirus Vaccine Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Patent Analysis

7. Global Human Papillomavirus Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Valence (Bivalent, Quadrivalent, Nonvalent, Others)
    • 7.2.2. By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others)
    • 7.2.3. By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others)
    • 7.2.4. By Region
    • 7.2.5. By Company (2022)
  • 7.3. Market Map
    • 7.3.1. By Valence
    • 7.3.2. By Disease Indication
    • 7.3.3. By Distribution Channel
    • 7.3.4. By Region

8. North America Human Papillomavirus Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Valence
    • 8.2.2. By Disease Indication
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Human Papillomavirus Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Valence
        • 8.3.1.2.2. By Disease Indication
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Mexico Human Papillomavirus Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Valence
        • 8.3.2.2.2. By Disease Indication
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Canada Human Papillomavirus Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Valence
        • 8.3.3.2.2. By Disease Indication
        • 8.3.3.2.3. By Distribution Channel

9. Europe Human Papillomavirus Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Valence
    • 9.2.2. By Disease Indication
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Human Papillomavirus Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Valence
        • 9.3.1.2.2. By Disease Indication
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Germany Human Papillomavirus Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Valence
        • 9.3.2.2.2. By Disease Indication
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. United Kingdom Human Papillomavirus Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Valence
        • 9.3.3.2.2. By Disease Indication
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. Italy Human Papillomavirus Vaccine Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Valence
        • 9.3.4.2.2. By Disease Indication
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Spain Human Papillomavirus Vaccine Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Valence
        • 9.3.5.2.2. By Disease Indication
        • 9.3.5.2.3. By Distribution Channel

10. Asia-Pacific Human Papillomavirus Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Valence
    • 10.2.2. By Disease Indication
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Human Papillomavirus Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Valence
        • 10.3.1.2.2. By Disease Indication
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. India Human Papillomavirus Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Valence
        • 10.3.2.2.2. By Disease Indication
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Japan Human Papillomavirus Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Valence
        • 10.3.3.2.2. By Disease Indication
        • 10.3.3.2.3. By Distribution Channel
    • 10.3.4. South Korea Human Papillomavirus Vaccine Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Valence
        • 10.3.4.2.2. By Disease Indication
        • 10.3.4.2.3. By Distribution Channel
    • 10.3.5. Australia Human Papillomavirus Vaccine Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Valence
        • 10.3.5.2.2. By Disease Indication
        • 10.3.5.2.3. By Distribution Channel

11. South America Human Papillomavirus Vaccine Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Valence
    • 11.2.2. By Disease Indication
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Human Papillomavirus Vaccine Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Valence
        • 11.3.1.2.2. By Disease Indication
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Argentina Human Papillomavirus Vaccine Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Valence
        • 11.3.2.2.2. By Disease Indication
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. Colombia Human Papillomavirus Vaccine Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Valence
        • 11.3.3.2.2. By Disease Indication
        • 11.3.3.2.3. By Distribution Channel

12. Middle East and Africa Human Papillomavirus Vaccine Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Valence
    • 12.2.2. By Disease Indication
    • 12.2.3. By Distribution Channel
    • 12.2.4. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Human Papillomavirus Vaccine Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Valence
        • 12.3.1.2.2. By Disease Indication
        • 12.3.1.2.3. By Distribution Channel
    • 12.3.2. Saudi Arabia Human Papillomavirus Vaccine Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Valence
        • 12.3.2.2.2. By Disease Indication
        • 12.3.2.2.3. By Distribution Channel
    • 12.3.3. UAE Human Papillomavirus Vaccine Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Valence
        • 12.3.3.2.2. By Disease Indication
        • 12.3.3.2.3. By Distribution Channel

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

  • 14.1. Recent Developments
  • 14.2. Mergers & Acquisitions
  • 14.3. Product Launches

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (As reported)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Serum Institute of India Pvt. Ltd.
    • 15.6.2. GlaxoSmithKline Plc.
    • 15.6.3. Johnson & Johnson
    • 15.6.4. Merck & Co., Inc.
    • 15.6.5. AstraZeneca Plc
    • 15.6.6. Novartis AG
    • 15.6.7. Inovio Pharmaceuticals, Inc.
    • 15.6.8. Xenetic Biosciences, Inc.
    • 15.6.9. Sanofi SA
    • 15.6.10. Bharat Biotech International Limited

16. Strategic Recommendations